We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AdenoVerse

News List

First Patient Dosed for AdenoVerse Immunotherapy for Recurrent Respiratory Papillomatosis americanpharmaceuticalreview
March 30, 2021
Precigen announced the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP).
Precigen Receives Orphan Drug Designation for PRGN-AdenoVerse™ Immunotherapy for Respiratory Papillomatosis americanpharmaceuticalreview
March 24, 2021
Precigen announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP).